Amwill Health Care Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 10039537,
    "name": "Amwill Health",
    "stock_name": "Amwill Health",
    "full_name": "Amwill Health Care Ltd",
    "name_url": "stocks-analysis/amwill-health",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "35.50",
    "chg": 0.52,
    "chgp": "1.49%",
    "dir": 1,
    "prev_price": "34.98",
    "mcapval": "70.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 544353,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0U2L01017",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": 36000,
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/amwill-health-10039537-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Amwill Health overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-amwill-health-overvalued-or-undervalued-3682998",
        "imagepath": "",
        "date": "2025-11-09 08:12:12",
        "description": "As of 7 November 2025, Amwill Health's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued. Key ratios supporting this assessment include a PE ratio of 9.06, an EV to EBIT of 7.64, and an ROCE of 18.23%. \n\nIn comparison to its peers, Amwill Health's valuation metrics stand out, particularly against Sun Pharma, which is deemed expensive with a PE ratio of 35.17, and Divi's Lab, classified as very expensive with a PE ratio of 71.11. This stark contrast highlights Amwill Health's attractive valuation within the pharmaceuticals and biotechnology sector. Additionally, while Amwill Health has experienced a decline in stock price recently, it remains undervalued relative to its peers, reinforcing the potential for future upside...."
      },
      {
        "title": "Is Amwill Health overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-amwill-health-overvalued-or-undervalued-3681968",
        "imagepath": "",
        "date": "2025-11-08 08:12:14",
        "description": "As of 7 November 2025, Amwill Health's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently deemed undervalued, with a PE ratio of 9.06, an EV to EBIT ratio of 7.64, and an EV to EBITDA ratio of 7.34. These figures suggest that Amwill Health is trading at a discount compared to its peers in the pharmaceuticals and biotechnology sector.\n\nIn comparison, Sun Pharma is classified as expensive with a PE ratio of 35.17, while Dr. Reddy's Labs is attractive with a PE of 17.43. This stark contrast highlights Amwill Health's favorable position in the market. Additionally, the company's return metrics, such as a ROCE of 18.23% and ROE of 14.68%, further reinforce its strong operational performance despite recent stock declines compared to the Sensex...."
      }
    ],
    "total": 174,
    "sid": "10039537",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/amwill-health-care-10039537"
  },
  "announcements": [
    {
      "caption": "Disclosuer Under Regulation 30 Of SEBI (LODR) Regulation 2015",
      "datetime": "16-Jan-2026",
      "details": "Intimation of approval for Investment in Vivriti Fixed Income Fund a scheme of Vivriti Vihaan Trust an Alternative Investment Fund (AIF) registered with SEBI as a Category II AIF and Goverment Securities (G-Sec).",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "10-Jan-2026",
      "details": "Compliance Certificate under Regulation 74(5) of the SEBI (Depositories and Participants ) Regulations 2018 for 3rd Quarter ended December 31 2025 of FY 2025-26.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Board Meeting Outcome For The Meeting Of The Board Of Directors Held On November 04 2025",
      "datetime": "04-Nov-2025",
      "details": "Disclosure under Regulation 30 and 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended (SEBI Listing Regulations) - Outcome of the meeting of the Board of Directors held on November 04 2025 and Approved Statement of Deviation(s) and variation(s) under Regulation 32 of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Amwill Health overvalued or undervalued?

2025-11-09 08:12:12

As of 7 November 2025, Amwill Health's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued. Key ratios supporting this assessment include a PE ratio of 9.06, an EV to EBIT of 7.64, and an ROCE of 18.23%. In comparison to its peers, Amwill Health's valuation metrics stand out, particularly against Sun Pharma, which is deemed expensive with a PE ratio of 35.17, and Divi's Lab, classified as very expensive with a PE ratio of 71.11. This stark contrast highlights Amwill Health's attractive valuation within the pharmaceuticals and biotechnology sector. Additionally, while Amwill Health has experienced a decline in stock price recently, it remains undervalued relative to its peers, reinforcing the potential for future upside....

Is Amwill Health overvalued or undervalued?

2025-11-08 08:12:14

As of 7 November 2025, Amwill Health's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently deemed undervalued, with a PE ratio of 9.06, an EV to EBIT ratio of 7.64, and an EV to EBITDA ratio of 7.34. These figures suggest that Amwill Health is trading at a discount compared to its peers in the pharmaceuticals and biotechnology sector. In comparison, Sun Pharma is classified as expensive with a PE ratio of 35.17, while Dr. Reddy's Labs is attractive with a PE of 17.43. This stark contrast highlights Amwill Health's favorable position in the market. Additionally, the company's return metrics, such as a ROCE of 18.23% and ROE of 14.68%, further reinforce its strong operational performance despite recent stock declines compared to the Sensex....

View All News